Catumaxomab for intraperitoneal treatment of malignant ascites caused by EpCAM-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 31 July 2026Expected publication date: TBC